key: cord-0920215-fwmh91f3 authors: Fuentes Carrasco, Marta; Mayoral Triana, Alejandra; Cristóbal García, Ignacio; Pérez Pérez, Noelia; Izquierdo Méndez, Nuria; Soler Ruiz, Patricia; González González, Virginia title: Catastrophic antiphospholipid syndrome during pregnancy date: 2021-07-07 journal: Eur J Obstet Gynecol Reprod Biol DOI: 10.1016/j.ejogrb.2021.07.002 sha: f7d9552a8f1f9318b9cbaa4fb67bf205b7215111 doc_id: 920215 cord_uid: fwmh91f3 Catastrophic antiphospholipid syndrome (CAPS) is an uncommon and the most severe form of antiphospholipid syndrome (APS). A 33-week pregnant patient with Klippel-Trenaunay syndrome, past SARS-CoV-2 infection and type I fetal growth restriction with shortening of the fetal long bone was diagnosed in our center with a probable CAPS. Cesarean section was performed four days after the diagnosis due to the torpid evolution of the patient. Clinical improvement was noted a few days later and the mother and baby were discharged within a week. We review the current literature on CAPS during pregnancy and provide an updated view. Antiphospholipid syndrome (APS) is an autoantibody-mediated acquired thrombophilia that is characterized by recurrent vascular thrombosis, thrombocytopenia and recurrent fetal loss, as well as the presence of three main antiphospholipid antibodies (anticardiolipin, lupus anticoagulant and antibeta2-glycoprotein). [2, 5] Catastrophic antiphospholipid syndrome (CAPS, Ronald Asherson syndrome) is the most severe form of antiphospholipid syndrome (APS) that results in a widespread coagulopathy and high titers of antiphospholipid antibodies (aPL). CAPS mainly affects the small vessels supplying organs, resulting in multiorgan failure. Ronald Asherson described it for the first time in 1992 as a potentially life-threatening variant of APS. This condition is rare, accounting for less than 1% of antiphospholipid syndrome cases, and is possibly triggered by pregnancy. Although CAPS develops in a very small number of patients with APS, mortality rates in affected patients are as high as one-third, so a proper diagnosis and emergency treatment are essential. [1, 3, 4] CASE REPORT A 20-year-old woman, gravida 1, arrived at 33+2 weeks gestation, complaining of pain in the fifth toe of her right foot and presented associated thrombocytopenia. Her pregnancy had been controlled by our High Risk Obstetrics Unit for a known history of antiphospholipid syndrome with high titers of the three antiphospholipid antibodies and 4 episodes of deep venous thrombosis, as well as a rare congenital syndrome called Klippel-Trenaunay syndrome (KTS). KTS is a complex congenital disorder historically defined as the triad of capillary malformation, venous malformation, and limb overgrowth, of unknown prevalence and incidence. In our patient this syndrome presented with agenesis of the infrarenal inferior vena cava, agenesis of the left iliac venous sector and lymphatic malformation in the lower limbs. Therefore, and due to her high thrombotic risk, she had been controlled and treated with warfarin until she got pregnant. In the first trimester of her pregnancy she suffered from SARS-CoV-2 infection and was diagnosed with type I fetal growth restriction at 26 weeks of pregnancy, in association with shortening of the fetal long bones (normal amniocentesis and negative immune serology with Rubella, Varicella, CMV, Parvovirus and Toxoplasma). Due to a history of non-pregnancy related thrombosis, Hematology modified her previous treatment from warfarin to tinzaparin 10,000 IU and aspirin 150 mg from the beginning of pregnancy. The examination revealed two very painful violaceous lesions on the 5th toe of the right foot as well as erythematous-violaceous plaques that disappeared on acupressure on the malar region, conserving the nasal dorsum. Blood test showed low platelets (78.000/microliter) and increased inflammatory parameters (ESR and CRP). Her renal function was deteriorated (estimated glomerular filtration rate dropping from 95 to 78 mL/min) with a protein/creatinine ratio <0.3, elevated liver enzymes (ALT 45 U/L; AST 54 U/L; GGT 41 U/L) and an increased activated partial thromboplastin time (APTT) ratio of 3.9 (possibly justified by the underlying antiphospholipid syndrome and the use of heparin). On account of the symptoms of pain and erythema in the fifth toe (without involvement of other toes) and a foot X-Ray that ruled out osteomyelitis, broad-spectrum antibiotic treatment was instated. A follow-up obstetric ultrasound was also performed, which revealed a breech presentation of a fetus with type I fetal growth restriction, a pathological mean uterine artery pulsatility index, and cerebro-placental index 12 weeks) Probable CAPS if only three out of the four criteria above are met